News By Tag
News By Location
SARC Investigator-Initiated Osteosarcoma Study Shows Positive Results of Regorafenib
Following the presentation at ASCO in June 2018 by Florence Duffaud, MD, on behalf of the French Sarcoma Group and Unicancer, SARC convened the study's Data Monitoring Committee (DMC) to review the unblinded data from SARC024 osteosarcoma group.The DMC determined that given the unequivocal and statistically significant progression-
"There have been many trials in the past 10 to 20 years demonstrating no evidence of benefit for people with metastatic osteosarcoma. Now, in my opinion, these data, along with similar data from the French REGOBONE study, serve as sound justification to use regorafenib for patients with metastatic osteosarcoma,"
"The encouraging results of this study are an example of how the environment of collaborative research can lead to important breakthroughs that improve outcomes for patients with sarcoma," said Denise Reinke, President and CEO of SARC.
On behalf of SARC and Dr. Maki, along with the cohort PIs Dr. Lara Davis and Dr. Christopher W. Ryan and all the SARC024 investigators, we appreciate all the patients and their families who agreed to be a part of this important study.
A full manuscript report is being prepared. More details will be announced.
SARC024 is an investigator-
About the PIs
The osteosarcoma group Principal Investigators are Christopher W. Ryan, MD, Medical Oncologist, Oregon Health and Science University; and Lara Davis, MD, Instructor, Department of Medicine and Pediatrics/Adult Medical Oncology, Oregon Health and Science University. The SARC024 overall Principal Investigator is Robert Maki, MD, PhD, Professor of Medicine, Northwell Cancer Institute / Zucker School of Medicine at Hofstra-Northwell, and Professor, Cold Spring Harbor Laboratory.
SARC (Sarcoma Alliance for Research Through Collaboration)
Charlene Calcagno, SARC
Sr. Manager of Administrative Services